Live tape
Top 8, mentions 7d30,212NVDA14,254 mentions▲ +0.04ANT4,320 mentions▲ +0.07GOOGL3,151 mentions▲ +0.04SPY2,363 mentions▲ +0.05QQQ1,870 mentions▲ +0.04SPCX1,605 mentions▲ +0.07AMD1,389 mentions▲ +0.06AAPL1,260 mentions▲ +0.04

Equity · Healthcare

IONS

NASDAQ

Ionis Pharmaceuticals (IONS)

26.61 USD −2.31% vs prior close Nov 20, 2026
Ionis Pharmaceuticals, Inc. price graph
63 sessions
80 20 24 Aug 20 Nov

The line runs 62 USD on 24 August through 26.61 USD on 20 November, on a scale from 20 to 80. Days the market did not trade hold the previous close, flat.

Market cap
4.4B USD
Revenue, year to Dec 2025
943.7M USD
EPS, diluted, year to Dec 2025
−2.38 USD
52-week range
26.61 USD – 86.52 USD
Avg volume
245.7K
Mentions, 30 days
2

as of Nov 20, 2026

Have Ionis Pharmaceuticals (IONS) insiders bought or sold shares recently?

In the 90 days to 23 Nov 2026, Ionis Pharmaceuticals insiders reported 2 open-market sales and 1 purchase (SEC Form 4).

Form 4, 90 days to 23 Nov 2026, newest reported trade 10 Nov 2026

1buys
2sells
$87Knet bought
6other filings
Have Ionis Pharmaceuticals (IONS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
10 Nov 2026Hayden Michael RDirectorBuy5,000148K USD
16 Oct 2026Devers Shannon L.EVP, Chief Human Resources OfcSell1,35759K USD
16 Oct 2026Swayze EricEVP ResearchSell532K USD
Bought1 open-market purchase5,000$148K
Sold2 open-market sales1,410$61K
6 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Ionis Pharmaceuticals (IONS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
15 Oct 2026Devers Shannon L.EVP, Chief Human Resources OfcOption exercise2,820
15 Oct 2026Swayze EricEVP ResearchOption exercise125
31 Aug 2026BENNETT C FRANKEVP, Chief Scientific OfficerOther1106K USD
31 Aug 2026O'NEIL PATRICK R.EVP CLO & General CounselOther633K USD
31 Aug 2026Monia Brett PChief Executive OfficerOther985K USD
31 Aug 2026Birchler BrianEVP, Corp and Development OpsOther583K USD

Which funds hold Ionis Pharmaceuticals (IONS)?

14 of the 45 institutional funds we track reported a Ionis Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 725.2M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Ionis Pharmaceuticals (IONS)?
FundPositionSharesValueShares q/q
Two Sigma InvestmentsHeld (±25%)6,727,410300.4M USD+7.6%
Citadel AdvisorsAdded4,026,275179.8M USD+1,604.0%
Point72 Asset ManagementNew position1,227,78854.8M USD
Baker Bros. AdvisorsTrimmed1,023,86445.7M USD−50.0%
ARK Investment ManagementAdded923,16241.2M USD+206.9%
Millennium ManagementAdded750,78533.5M USD+159.9%
D. E. Shaw & Co.Added543,13024.3M USD+82.8%
Renaissance TechnologiesTrimmed354,21415.8M USD−36.7%
Balyasny Asset ManagementNew position298,82813.3M USD
Fisher Asset ManagementAdded182,9978.2M USD+33.4%

Showing the 10 largest of 14 reported positions. The figures above count all of them.

Have members of Congress traded Ionis Pharmaceuticals (IONS)?

The most recent congressional trade disclosed in Ionis Pharmaceuticals is a sale by Daniel S. Goldman (house, NY), dated 06 Mar 2023.

STOCK Act disclosures

Have members of Congress traded Ionis Pharmaceuticals (IONS)?
TradedMemberTypeAmountFiled after
06 Mar 2023Daniel S. Goldmanhouse · Democrat–NYSale1K USD–15K USD42 days

What has been filed or recorded for Ionis Pharmaceuticals (IONS)?

The filings we hold for Ionis Pharmaceuticals, newest first: 3 fails-to-deliver days, 7 quarterly earnings reports, 1 annual report and 5 reported financial figures, the latest dated 26 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Ionis Pharmaceuticals (IONS)?
And
26 Oct 2026Fails to deliverShares failed to deliver879 shares38K USD notional · 0.001% of shares out
20 Oct 2026Fails to deliverShares failed to deliver19,578 shares869K USD notional · 0.012% of shares out
09 Oct 2026Fails to deliverShares failed to deliver14,082 shares610K USD notional · 0.008% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.66 USD
30 Sep 2026FinancialsTotal assets2.9B USDat period end
30 Sep 2026FinancialsTotal equity393.6M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.69 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.56 USD
31 Dec 2025Quarterly earningsQ2 2025 reportedEPS 0.70 USD
31 Dec 2025FinancialsRevenue943.7M USDfiscal year
31 Dec 2025FinancialsNet income−381.4M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−2.38 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.80 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS 0.70 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.93 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −0.66 USDRevenue $227M

What is Reddit saying about Ionis Pharmaceuticals (IONS)?

Reddit mentioned IONS 2 times in the 30 days to 22 November 2026, across 2 of the communities we track. All of them were scored for sentiment: 50% read bullish, 0% bearish and 50% neither. Reddit data updated 22 November 2026.

30-day window, Method

2mentions, 30 days
2communities

How do Reddit mentions of Ionis Pharmaceuticals (IONS) compare with its price?

Share ↗
2 mentions

Which subreddits are talking about Ionis Pharmaceuticals (IONS)?

30 days

Which subreddits are talking about Ionis Pharmaceuticals (IONS)?
CommunityShareMentionsNet sentiment
r/stocks50%1−0.01
r/wallstreetbets50%1+0.09

What do people ask about Ionis Pharmaceuticals (IONS)?

From live data
What did Ionis Pharmaceuticals shares close at?26.61

Ionis Pharmaceuticals closed at 26.61 USD on 20 Nov 2026, down 2.31% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Ionis Pharmaceuticals’ market cap?4.4B

Ionis Pharmaceuticals is worth 4.4B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Ionis Pharmaceuticals’ revenue?943.7M

Ionis Pharmaceuticals reported revenue of 943.7M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Ionis Pharmaceuticals insiders bought or sold shares recently?2 sales

In the 90 days to 23 Nov 2026, Ionis Pharmaceuticals insiders reported 2 open-market sales and 1 purchase (SEC Form 4). A further 6 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Ionis Pharmaceuticals?14 of 45

14 of the 45 funds we track reported a Ionis Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Citadel Advisors and Point72 Asset Management. See Funds

Have members of Congress traded Ionis Pharmaceuticals?1 trade

Yes. 1 trade in Ionis Pharmaceuticals appears in the congressional disclosures we hold: a sale by Daniel S. Goldman (House, NY) dated 6 Mar 2023, filed 17 Apr 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

When did Ionis Pharmaceuticals last report earnings?−0.66

Ionis Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.66 USD; no next date is announced in SEC filings yet. See Filings

What is Reddit saying about Ionis Pharmaceuticals?0 mentions

Ionis Pharmaceuticals was mentioned 0 times in the last 7 days across the finance subreddits we track, and 2 times over the trailing 30 days. Of the 2 mentions scored for sentiment, 50% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. RedditReddit ingest across the tracked finance subreddits
  4. SEC EDGARForm 4 filings (insider transactions)
  5. SEC EDGAR13F filings
  6. Wikimedia CommonsPortraits via Wikimedia Commons. Daniel S. Goldman: US House, Public domain.
  7. House disclosuresU.S. House of Representatives financial disclosures
  8. SECSEC fails-to-deliver (CNS) data
  9. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  10. SEC EDGARreported earnings figures and scheduled report dates
  11. SEC EDGARValuation computed from SEC EDGAR filings
  12. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words